Unveiling a specific immunogen protein in A. baumannii

Authors
K. Ahmadi Zanoos 1
I. Rasooli 1
A. Jahangiri 2
M. R. Rahbar 3
S. Darvish Alipour Astaneh 1
1 Department of Biology, Faculty of Basic Sciences, Shahed University, Tehran, Iran
2 Applied Microbiology Research Center, Baqiyatallah University of Medical Sciences, Tehran, Iran
3 Department of Molecular Biology, Dr. Saadati’s Laboratory, Shiraz, Iran
Abstract
Objectives: Acinetobacter baumannii is a Gram-negative, non-motile aerobic bacterium known as a nosocomial pathogen resisting often to broad range of antibiotics. The pathogen is a serious agent of mortality and morbidity in hospital particularly among immunocompromise patients. Treatment and control of its infections is complicated owing to its high antibiotic resistance, survival in various environmental conditions and utilization of wide range of nutrient sources. Early detection of the pathogen in established infections is pivotal for controlling the infections. Culture and biochemical test are current methods for detection of the bacterium taking 2-5 days time. Hence, a new rapid specific affordable diagnostic test is needed. Development of such test depends on a suitable biomarker without any cross reactivity with other bacteria. Methods: Accordingly, aim of the study is to unveil of a 34.4 KDa outer membrane protein (OMP) introduced by Islam et al. in A. baumannii ATCC19606. In the current study, we harnessed various bioinformatic servers to screen whole proteome of the bacterium. Properties critical to the screening include: molecular weight, localization, topology, homology, antigenicity and allergenicity of proteins. Results: Three proteins were found as suitable candidate molecular weight as well as localization points of view. BLAST searches, antigen probability predictions and other analyses led to selection of one protein as the best specific antigen of A. baumannii. Conclusion: The in silico analyses unveiled the best candidate protein vide accession number ZP_05827218.1.

Keywords

 [1]     Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA. Global challenge of multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2007; 51(10): 3471-84.
[2]     Huang HI, Shih HY, Lee CM, Yang TC, Lay JJ, Lin YE. In vitro efficacy of copper and silver ions in eradicating Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Acinetobacter baumannii: implications for on-site disinfection for hospital infection control. Water Res 2008; 42(1-2): 73-80.
[3]     Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol 2007; 5(12): 939-51.
[4]     Scott P, Deye G, Srinivasan A, Murray C, Moran K, Hulten E, Fishbain J, Craft D, Riddell S, Lindler L, Mancuso J, Milstrey E, Bautista CT, Patel J, Ewell A, Hamilton T, Gaddy C, Tenney M, Christopher G, Petersen K, Endy T, Petruccelli B. An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clin Infect Dis 2007; 44(12): 1577-84.
[5]     Davis KA, Moran KA, McAllister CK, Gray PJ. Multidrug-resistant Acinetobacter extremity infections in soldiers. Emerg Infect Dis 2005; 11(8): 1218-24.
[6]     Yavankar SP, Pardesi KR, Chopade BA. Species distribution and physiological characterization of Acinetobacter genospecies from healthy human skin of tribal population in India. Indian J Med Microbiol 2007; 25(4): 336-45.
[7]     Jeong SH, Bae IK, Park KO, An YJ, Sohn SG, Jang SJ, Sung KH, Yang KS, Lee K, Young D, Lee SH. Outbreaks of imipenem-resistant Acinetobacter baumannii producing carba-penemases in Korea. J Microbiol 2006; 44(4): 423-31.
[8]     Falagas ME, Bliziotis IA, Siempos II. Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 2006; 10(2): R48.
[9]     Hanberger H, Garcia-Rodriguez JA, Gobernado M, Goossens H, Nilsson LE, Struelens MJ. Antibiotic susceptibility among aerobic gram-negative bacilli in intensive care units in 5 European countries. French and Portuguese ICU Study Groups. JAMA 1999; 281(1): 67-71.
[10] Wisplinghoff H, Bischoff T, Tallent SM, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. Clin Infect Dis 2004; 39(3): 309-17.
[11] Ghrbanalizadegan M. The Prevalence of Multi-Resistant Pseudomonas aeruginosa and Acinetobacter spp. in Patients Addmited in Baqiyatallah Hospital in 2005. J Ilam University of Medical Sciences 2007; 15(1): 14-18
[12] Gordon NC, Wareham DW. Multidrug-resistant Acinetobacter baumannii: mechanisms of virulence and resistance. Int J Antimicrob Agents 2010; 35(3): 219-26.
[13] Tomaras AP, Dorsey CW, Edelmann RE, Actis LA. Attachment to and biofilm formation on abiotic surfaces by Acinetobacter baumannii: involvement of a novel chaperone-usher pili assembly system. Microbiology 2003; 149(Pt 12): 3473-84.
[14] Lee HW, Koh YM, Kim J, Lee JC, Lee YC, Seol SY, Cho DT, Kim J. Capacity of multidrug-resistant clinical isolates of Acinetobacter baumannii to form biofilm and adhere to epithelial cell surfaces. Clin Microbiol Infect 2008; 14(1): 49-54.
[15] Cevahir N, Demir M, Kaleli I, Gurbuz M, Tikvesli S. Evaluation of biofilm production, gelatinase activity, and mannose-resistant hemagglutination in Acinetobacter baumannii strains. J Microbiol Immunol Infect 2008; 41(6): 513-8.
[16] Vidal R, Dominguez M, Urrutia H, Bello H, Gonzalez G, Garcia A, Zemelman R. Biofilm formation by Acinetobacter baumannii. Microbios 1996; 86(346): 49-58.
[17] Rathinavelu S, Zavros Y, Merchant JL. Acinetobacter lwoffii infection and gastritis. Microbes Infect 2003; 5(7): 651-7.
[18] Talbot GH. What is in the pipeline for Gram-negative pathogens? Expert Rev Anti Infect Ther 2008; 6(1): 39-49.
[19] Levin AS. Multiresistant Acinetobacter infections: a role for sulbactam combinations in overcoming an emerging worldwide problem. Clin Microbiol Infect 2002; 8(3): 144-53.
[20] Islam AH, Singh KK, Ismail A. Demonstration of an outer membrane protein that is antigenically specific for Acinetobacter baumannii. Diagn Microbiol Infect Dis 2011; 69(1): 38-44.
[21] Rahbar MR, Rasooli I, Gargari SL, Sandstrom G, Amani J, Fattahian Y, Jahangiri A, Jalali M. A potential in silico antibody-antigen based diagnostic test for precise identification of Acinetobacter baumannii. J Theor Biol 2012; 294: 29-39.
[22] Jahangiri A, Rasooli I, Reza Rahbar M, Khalili S, Amani J, Ahmadi Zanoos K. Precise detection of L. monocytogenes hitting its highly conserved region possessing several specific antibody binding sites. J Theor Biol 2012; 305: 15-23.
[23] Jahangiri A, Rasooli I, Gargari SL, Owlia P, Rahbar MR, Amani J, Khalili S. An in silico DNA vaccine against Listeria monocytogenes. Vaccine 2011; 29(40): 6948-58.
[24] Rahbar MR, Rasooli I, Mousavi Gargari SL, Amani J, Fattahian Y. In silico analysis of antibody triggering biofilm associated protein in Acinetobacter baumannii. J Theor Biol 2010; 266(2): 275-90.
[25] Sefid F, Rasooli I, Jahangiri A. In silico determination and validation of baumannii acinetobactin utilization a structure and ligand binding site. BioMed Res Int 2013; 2013, Article ID 172784, 14 pages, Available at: http://dx.doi.org/10.1155/2013/172784
[26] Sugawara E, Nikaido H. OmpA is the principal nonspecific slow porin of Acinetobacter baumannii. J Bacteriol 2012; 194(15): 4089-96.
[27] Toobak H, Rasooli I, Talei D, Jahangiri A, Owlia P, Darvish Alipour Astaneh S. Immune response variations to Salmonella enterica serovar Typhi recombinant porin proteins in mice. Biologicals 2013; 41(4): 224-30.
[28] Toobak H, Rasooli I, Mousavi Gargari SL, Jahangiri A, Jalali Nadoushan MR, Owlia P, Darvish Alipour Astaneh S. Characterization of the Salmonella typhi outer membrane protein C. Korean J Microbiol Biotechnol 2013; 41(1): 128-34.
[29] Doytchinova IA, Flower DR. VaxiJen: a server for prediction of protective antigens, tumour antigens and subunit vaccines. BMC Bioinformatics 2007; 8: 4.
[30] Novotny J, Rigoutsos I, Coleman D, Shenk T. In silico structural and functional analysis of the human cytomegalovirus (HHV5) genome. J Mol Biol 2001; 310(5): 1151-66.
[31] Fattahian Y, Rasooli I, Mousavi Gargari SL, Rahbar MR, Darvish Alipour Astaneh S, Amani J. Protection against Acinetobacter baumannii infection via its functional deprivation of biofilm associated protein (Bap). Microb Pathog 2011; 51(6): 402-6.
[32] Soares NC, Cabral MP, Parreira JR, Gayoso C, Barba MJ, Bou G. 2-DE analysis indicates that Acinetobacter baumannii displays a robust and versatile metabolism. Proteome Sci 2009; 7: 37.
[33] Al-Hasani K, Boyce J, McCarl VP, Bottomley S, Wilkie I, Adler B. Identification of novel immunogens in Pasteurella multocida. Microbial Cell Factories 2007; 6: 3.
[34] Emanuelsson O, Brunak S, von Heijne G, Nielsen H. Locating proteins in the cell using TargetP, SignalP and related tools. Nat Protoc 2007; 2(4): 953-71.
[35] Lin XM, Li H, Wang C, Peng XX. Proteomic analysis of nalidixic acid resistance in Escherichia coli: identification and functional characterization of OM proteins. J Proteome Res 2008; 7(6): 2399-405.
[36] Van Regenmortel MH. What is a B-cell epitope? Methods Mol Biol 2009; 524: 3-20.
[37] Dashper SG, Hendtlass A, Slakeski N, Jackson C, Cross KJ, Brownfield L, Hamilton R, Barr I, Reynolds EC. Characterization of a novel outer membrane hemin-binding protein of Porphyromonas gingivalis. J Bacteriol 2000; 182(22): 6456-62.
Pathobiology Reserach
Volume 17, Issue 1
April 2014
Pages 1-16